These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20546921)

  • 1. The challenges of product development and commercialization in a convergence technology world: focus on regenerative medicine.
    Tozer D
    Drug Discov Today; 2010 Aug; 15(15-16):587-9. PubMed ID: 20546921
    [No Abstract]   [Full Text] [Related]  

  • 2. Achieving reimbursement for regenerative medicine products in the USA.
    Ginty PJ; Singh PB; Smith D; Hourd P; Williams DJ
    Regen Med; 2010 May; 5(3):463-9. PubMed ID: 20455656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced Tissue Sciences Inc.: learning from the past, a case study for regenerative medicine.
    Pangarkar N; Pharoah M; Nigam A; Hutmacher DW; Champ S
    Regen Med; 2010 Sep; 5(5):823-35. PubMed ID: 20868336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.
    Plagnol AC; Rowley E; Martin P; Livesey F
    Regen Med; 2009 Jul; 4(4):549-59. PubMed ID: 19580404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reimbursement and adoption of advanced therapies: the 5-C framework.
    Malik NN
    Regen Med; 2014; 9(5):573-8. PubMed ID: 25372076
    [No Abstract]   [Full Text] [Related]  

  • 6. Conference scene: Challenges to commercialization.
    Ilic D; Gentleman E
    Regen Med; 2010 May; 5(3):341-3. PubMed ID: 20455647
    [No Abstract]   [Full Text] [Related]  

  • 7. Hurdles in tissue engineering/regenerative medicine product commercialization: a survey of North American academia and industry.
    Johnson PC; Bertram TA; Tawil B; Hellman KB
    Tissue Eng Part A; 2011 Jan; 17(1-2):5-15. PubMed ID: 20726816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The commercialization of regenerative medicine into a routine healthcare offering. Interview by Emily Culme-Seymour.
    Deans R
    Regen Med; 2013 May; 8(3):251-6. PubMed ID: 23634984
    [No Abstract]   [Full Text] [Related]  

  • 9. Regenerative Medicine Venturing at the University-Industry Boundary: Implications for Institutions, Entrepreneurs, and Industry.
    Bock AJ; Johnson D
    Adv Exp Med Biol; 2018; 1098():213-236. PubMed ID: 30238374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commercialization of regenerative medicine: learning from spin-outs.
    French A; Buckler RL; Brindley DA
    Rejuvenation Res; 2013 Apr; 16(2):164-70. PubMed ID: 23470045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From innovation to successful commercialization: assessing value and investment--does the equation make sense?
    Toneguzzo F
    Surgery; 2008 Feb; 143(2):165-8. PubMed ID: 18242328
    [No Abstract]   [Full Text] [Related]  

  • 12. The economic value of investing in regenerative medicine.
    Hussain A; Rivers PA
    J Health Care Finance; 2009; 36(2):45-54. PubMed ID: 20499720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Centre for Commercialization of Regenerative Medicine: moving forward with regenerative medicine commercialization in Canada.
    Johnson S
    Stem Cells Dev; 2013 Dec; 22 Suppl 1():85-8. PubMed ID: 24304082
    [No Abstract]   [Full Text] [Related]  

  • 14. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement.
    Bubela T; McCabe C; Archibald P; Atkins H; Bradshaw SE; Kefalas P; Mujoomdar M; Packer C; Piret J; Raxworthy M; Soares M; Viswanathan S
    Regen Med; 2015; 10(7):897-911. PubMed ID: 26565607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regenerative medicine, resource and regulation: lessons learned from the remedi project.
    Ginty PJ; Rayment EA; Hourd P; Williams DJ
    Regen Med; 2011 Mar; 6(2):241-53. PubMed ID: 21391857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regenerative medicine: learning from past examples.
    Couto DS; Perez-Breva L; Cooney CL
    Tissue Eng Part A; 2012 Nov; 18(21-22):2386-93. PubMed ID: 22697402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Commercialization," a perspective.
    Platt AC; Evans RW; Platt JL
    Surgery; 2008 Feb; 143(2):157-61. PubMed ID: 18242325
    [No Abstract]   [Full Text] [Related]  

  • 18. The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics.
    Mahalatchimy A; Faulkner A
    Regen Med; 2017 Sep; 12(6):611-622. PubMed ID: 28972450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The industrialization of regenerative medicine--a potential market of $ 500 billion].
    Gu Q; Zhang X; Jiang L
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Sep; 21(9):1011-5. PubMed ID: 17933243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buying new technology.
    Health Aff (Millwood); 2008; 27(6):1619. PubMed ID: 18997220
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.